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Approximately 20% of unselected cases and 30% cytogenetically diploid cases of acute
myeloid leukemia (AML) and 80%of grade II–III gliomas and secondary glioblastomas carry
mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes. IDH1/2 mutations prevent
oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) and modulate the function
of IDH (neomorphic activity) thereby facilitating reduction of α-KG to D-2-hydroxyglutarate
(D-2HG), a putative oncometabolite. D-2HG is thought to act as a competitive inhibitor of
α-KG-dependent dioxygenases that include prolyl hydroxylases and chromatin-modifying
enzymes. The end result is a global increase of cellular DNA hypermethylation and alter-
ations of the cellular epigenetic state, which has been proposed to play a role in the
development of a variety of tumors. In this review, we provide an update on potential mol-
ecular mechanisms linking IDH1/2 mutations and the resulting oncometabolite, D-2HG,
with malignant transformation. In addition, in patients with AML and glioma we focus on
the associations between IDH1/2 mutations and clinical, morphologic, cytogenetic, and
molecular characteristics.
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INTRODUCTION
There is increasing evidence that alterations in cellular metabolism
are involved in the pathogenesis of many cancers. Notably, muta-
tions in three different enzymes in the tricarboxylic acid cycle are
associated with tumorigenesis. These enzymes are succinate dehy-
drogenease, fumarate hydratase, and isocitrate dehydrogenases
(IDH1 and 2) (Soga, 2013). As many of the intermediates in the
tricarboxylic acid cycle are important for synthesis of nucleotides,
lipids, and amino acids, it is not surprising that alterations in this
metabolic pathway may facilitate the development of cancers.
Somatic heterozygous mutations in IDH1 and IDH2 have been
recognized recently in a number of cancers. The first reported
mutation in an IDH-family gene was identified in a metastatic
colon cancer in 2006 (Sjöblom et al., 2006). In 2008, sequenc-
ing of glioblastoma multiforme (GBM) tumor samples identified
IDH1 mutations at R132 (IDH1R132) in 12% of tumors (Parsons
et al., 2008). In 2009, targeted mutational analysis of a broader
group of central nervous system tumors detected IDH1R132 muta-
tions in 70% of grade II and III gliomas (Yan et al., 2009). Also in
2009, whole-genome sequencing of a patient with acute myeloid
leukemia (AML) identified an IDH1R132 mutation (Mardis et al.,
2009). Subsequent analyzes on a large number of AML patients
treated on multiple clinical protocols confirmed the presence of
IDH1R132 mutations and also identified IDH2R140 and IDH2R172
mutations in∼20% of adult-onset AML with normal cytogenetics
(Mardis et al., 2009; Abbas et al., 2010; Boissel et al., 2010; Green
et al., 2010; Gross et al., 2010; Ho et al., 2010; Marcucci et al., 2010;
Paschka et al., 2010; Schnittger et al., 2010; Thol et al., 2010a).
These mutations also have been identified, albeit at much lower
frequency, in myelodysplastic syndromes and myeloproliferative
neoplasms (Abbas et al., 2010; Green and Beer, 2010; Paschka et al.,
2010; Tefferi et al., 2010; Thol et al., 2010b). Recently, a number
of other tumors have been identified to harbor IDH mutations
including angioimmunoblastic T-cell lymphoma (Cairns et al.,
2012), chondrosarcoma (Amary et al., 2011), and intrahepatic
cholangiocarcinoma (Borger et al., 2012; Wang et al., 2012).
Isocitrate dehydrogenase 1 and 2 mutations reduce the affinity
of their respective enzymes for isocitrate and increase their affin-
ity for α-ketoglutarate (α-KG) and reduced nicotinamide adenine
dinuceotide phosphate (NADPH). This reduced affinity impedes
oxidative decarboxylation of isocitrate to α-KG and confers a
novel enzymatic activity that facilitates reduction of α-KG to d-2-
hydroxyglutarate (d-2HG) (Dang et al., 2009; Pietrak et al., 2011).
Excess accumulation of d-2HG has been demonstrated in a sub-
set of cases of glioma and AML with IDH1 or IDH2 mutations
(Dang et al., 2009; Frezza et al., 2010; Gross et al., 2010; Ward
et al., 2010; Andersson et al., 2011; Rakheja et al., 2011a; Choi
et al., 2012). Others have suggested that overproduction of d-2HG
promotes oncogenesis (Koivunen et al., 2012; Losman et al., 2013)
and therefore IDH1 and IDH2 mutations are likely the integrally
involved in the pathogenesis of malignant transformation (i.e.,
driver mutations) rather than epiphenomena.
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In this review, we summarize the frequency and role of IDH1
and IDH2 mutations in gliomas and myeloid neoplasms, the latter
with an emphasis on AML, and the association of these mutations
with clinical, morphologic, cytogenetic, and molecular character-
istics. We also provide an update on potential molecular mecha-
nisms linking mutant IDH1 and IDH2 and their oncometabolite,
d-2HG, with malignant transformation. The data suggest that
IDH1/2 mutations constitute an early mutational event which
affects the cellular epigenetic state in a subset of gliomas and AML,
an important consideration for the development of therapeutic
agents.
BIOCHEMISTRY OF ISOCITRATE DEHYDROGENASES
In mammalian cells, three classes of IDH isoenzymes exist: IDH1,
IDH2, and IDH3 (Plaut et al., 1983). The human IDH1 enzyme
is localized in the cytoplasm and peroxisomes and is encoded by
IDH1 at chromosome band 2q33.3 (Narahara et al., 1985; Geis-
brecht and Gould, 1999). The IDH2 enzyme is localized in mito-
chondria and is encoded by IDH2 at chromosome band 15q26.1
(Oh et al., 1996). The IDH1 and IDH2 enzymes are homod-
imeric, nicotinamide adenine dinucleotide phosphate-dependent,
and catalyze the oxidative decarboxylation of isocitrate to α-
KG, using NADP as a cofactor to yield NADPH (Haselbeck and
McAlister-Henn, 1993). Mitochondrial NADPH participates in
energy metabolism, as a part of the tricarboxylic acid cycle, and
cytosolic NADPH, which is also produced in the pentose phos-
phate pathway, functions in anabolic processes and redox control.
It is therefore reasonable to expect that changes in one or more
of these processes occur in tumors that carry an IDH1 or IDH2
mutation. The NAD-dependent IDH3 is a heterotetramer com-
posed of two alpha subunits (gene on chromosome 15), one beta
subunit (gene on chromosome 20), and one gamma subunit (gene
on chromosome X). IDH3 has not been shown to be mutated in
cancer and therefore is not further addressed in this review.
NEOMORPHIC ACTIVITY OF IDH1/IDH2 MUTANT ENZYMES
Most cancer-associated enzyme mutations result in either catalytic
inactivation or constitutive activation. A common feature of IDH1
and IDH2 mutations observed in AML and gliomas, however,
is the apparent acquisition of enzymatic activity not shared by
wild-type enzyme, known as neomorphic activity. The product of
IDH1/IDH2 mutations,d-2HG, can be detected in tumor samples.
To date, all reported IDH1or IDH2 mutations are heterozygous,
with cancer cells retaining one wild-type copy of the respective
IDH1 or IDH2 allele. All IDH mutations identified involve a sin-
gle amino acid substitution at an arginine (R) residue, R132 in
IDH1, or R140 or R172 in IDH2; no inactivating (frame-shift or
protein-truncation) mutations have been found. These residues
create hydrophilic interactions that allow the binding of isocitrate
(Xu et al., 2004). The residues that are substituted for arginine are
wide ranging, and include histidine, serine, cysteine, glycine, or
leucine, suggesting that it is the replacement of arginine, and not
the specific amino acid substituted, that supports tumorigenesis.
In vitro enzymatic analysis has confirmed that mutant IDH1
and IDH2 have altered substrate specificity and directionality
(Dang et al., 2009; Zhao et al., 2009; Gross et al., 2010; Ward
et al., 2010; Andersson et al., 2011; Pietrak et al., 2011). IDH1
R132 and IDH2 R172 are analogous residues that interact with the
β-carboxyl of isocitrate. Normally, IDH functions as a homod-
imer; by contrast mutant IDH molecules in tumor cells form
heterodimers with wild-type molecules. Whereas WT IDH con-
verts isocitrate to α-KG, mutants of IDH can no longer catalyze
this reaction and instead reduce α-KG to the d-stereoisomer of
2-hydroxyglutarate (d-2HG) (Figure 1). Structural comparisons
of mutant and wild type IDH1 have revealed that mutations at
R132 of IDH1 result in impaired enzyme affinity for substrate
and dominantly inhibit wild-type IDH1 activity through the for-
mation of catalytically inactive heterodimers. The R132 mutation
also changes the orientation of the catalytic site so that the enzyme
binds NADPH and α-KG, explaining the formation of the new
product, rather than simply catalyzing the reaction in reverse. In
support of the results of in vitro enzymatic analyzes, d-2HG levels
are 100-fold higher in cases of glioma and AML that carry IDH1
or IDH2 mutations as compared with tumors with wild type IDH
(Dang et al., 2009; Gross et al., 2010; Ward et al., 2010; Andersson
et al., 2011). Therefore, detecting d-2HG in tumor samples can
reliably predict patients with tumor-associated IDH mutations
(Gross et al., 2010).
MECHANISM OF IDH MUTATIONS IN TUMORIGENESIS
The discovery of IDH mutations has led to renewed efforts
to decipher the role of altered metabolic processes in can-
cer (Prensner and Chinnaiyan, 2011). The normal metabolic
role of 2-hydroxyglutarate is not completely understood, but
2-hydroxyglutarate is not foreign to cells. It can be generated
by specific α-KG reductase enzymes and oxidized back to α-
KG by 2-hydroxyglutarate dehydrogenases (2HGDH). There are
two enantiomers of 2-hydroxyglutarate with specific 2HGDH
for each. Mutations in 2HGDH cause pathological accumu-
lation of 2-hydroxyglutarate with different clinical features
based on the enantiomer involved. Pathological accumulation
of the l-2-hydroxyglutarate enantiomer (l-2HG) is known to
occur in a rare inherited autosomal recessive disease charac-
terized by encephalopathy and increased risk of brain tumors,
including gliomas (Aghili et al., 2009). Accumulation of the
d-2-hydroxyglutarate enantiomer (d-2HG) is associated with
encephalopathy and cardiomyopathy, but not with tumors (Struys,
2006). Mutant IDH in cases of AML and glioma generates d-2HG
and not the l-enantiomer.
As a result of IDH mutation, the oncometabolite of d-2HG
is produced and α-KG is reduced. The combination of these
two events may be important. At the high levels of d-2HG that
have been observed in cases of AML and glioma (more than
10 mM) (Dang et al., 2009; Gross et al., 2010; Ward et al., 2010;
Andersson et al., 2011), d-2HG may lead to DNA damage medi-
ated by elevated levels of reactive oxygen species (Zhao et al.,
2009; Ward et al., 2010), induction of redox stress owing to
impairment of the respiratory chain, promotion of oncogene-
sis by promoting cytokine independence, and blocking differ-
entiation in hematopoietic cells (Losman et al., 2013). Notably,
d-2HG and α-KG are structurally similar except that the oxy-
gen atom linked to C2 in α-KG is replaced by a hydroxyl group
in d-2HG. This structural similarity suggests that d-2HG might
exert its oncogenic effects through competitive inhibition with
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FIGURE 1 | Normal and neomorphic reactions catalyzed by IDH.
The normal enzyme catalyzes the nicotinamide adenine dinucleotide
phosphate (NADP+)-dependent conversion of isocitrate to α-KG, while
the mutant enzyme (neomorphic reaction in red) catalyzes the
reduction of α-KG to D-2HG, a reaction that depends on NADPH (the
reduced form of NADP+). D-2HGDH, D-2-hydroxyglutarate
dehydrogenase; HOT, hydroxyacid oxoacid transhydrogenase; IDH,
isocitrate dehydrogenase; IDH′, mutant isocitrate dehydrogenase;
L-2HGDH, L-2-hydroxyglutarate dehydrogenase; MDH, malate
dehydrogenase; TCA, tricarboxylic acid.
α-KG-dependant dioxygenases (Figueroa et al., 2010; Chowd-
hury et al., 2011; Xu et al., 2011). These enzymes include prolyl
hydroxylases, and chromatin-modifying enzymes, such as histone
demethylases and TET 5-methylcytosine hydroxylases.
TET2 is an α-KG-utilizing enzyme that hydroxylates 5-
methylcytosine as a step in demethylation of DNA (Ito et al.,
2010). Recently, all TET family members including TET2 were
shown to catalyze the conversion of 5-methylcytosine to 5-
hydroxymethylcytosine (5-OH-MeC) (Ito et al., 2010). The fact
that IDH1 and IDH2 mutations are mutually exclusive, and that
IDH1/2 mutations are mutually exclusive with TET2 mutations,
suggests that the biological effects of mutant IDH1/2 and TET
are similar (Figueroa et al., 2010; Chou et al., 2011a; Patel et al.,
2012). AMLs with TET2 or IDH mutation, and IDH mutated
gliomas have more pronounced hypermethylation profiles than
their non-mutated counterparts and share overlapping epigenetic
signatures (Figueroa et al., 2010; Xu et al., 2011). Most impor-
tantly, expression of IDH1/2 mutants induces a global increase in
global DNA hypermethylation and inhibits TET2-induced cyto-
sine 5-hydroxymethylation due to reduction of α-KG. These data
suggest that TET2 and IDH1/2 mutations characterize a distinc-
tive group of AML cases in which the epigenetic state is altered.
Many of the genes hypermethylated in the context of IDH1/2
mutated AML contain DNA-binding motifs for GATA1/GATA2
and EVI1, transcription factors known to play a role in leukemo-
genesis as well as normal myeloid differentiation (Figueroa et al.,
2010).
Recent analysis of gliomas also has shown that IDH1 gene
mutations represent a molecular basis for the epigenetic changes
described above. In one study, the methylation profiles of immor-
talized primary human astrocytes in which either wild-type
IDH1 or R132H IDH1 was introduced were analyzed using a
genome-wide platform. Expression of wild-type IDH1 led to
hypomethylation at several loci, compared with a marked increase
in methylation seen in the R132H IDH1 mutants. The methy-
lation profiles of the IDH1 mutants mirrored the CpG island
methylator phenotype (CIMP), a unique phenotype seen in sev-
eral tumors with extensive epigenetic changes (Turcan et al.,
2012).
Histone lysine demethylases are another group of α-KG-
dependent enzymes. In vitro,d-2HG can inhibit histone demethy-
lases (Chowdhury et al., 2011; Xu et al., 2011). Experimental
data suggest that inhibition of histone demethylases can induce
DNA methylation (Lu et al., 2012). Methylated histones, such as
H3K9me3 (trimethylation of lysine 9 of histone H3), may serve
as a platform for recruiting a complex of heterochromatin protein
1 (HP1), histone methyltransferase, and DNA methytransferase.
Direct cooperation between these enzymes could then provide a
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mechanism of coordinated histone and DNA methylation involved
in epigenetic regulation of DNA (Estève et al., 2006).
Hypoxia-inducible factor 1α (HIF-1α) is a transcription factor
that has functions linked to metabolism,angiogenesis, and tumori-
genesis. HIF-1α protein levels are downregulated under nor-
moxic conditions by prolyl hydroxylase-mediated hydroxylation
and subsequent hydroxylation-targeted ubiquitination (Bruick
and McKnight, 2001). As α-KG is required by prolyl hydroxy-
lases, a reduction in α-KG levels in cancer cells with mutant IDH
may lead to inhibition of prolyl hydroxylases and stabilization
of HIF-1α (Zhao et al., 2009). An alternative mechanism pro-
posed by Koivunen et al. (2012) suggests that d-2HG acts as a
cofactor to promote the hydroxylase activity of the Eg1N prolyl-4-
hydroxylase and subsequent downregulation of HIF1α, contribut-
ing to the pathogenesis of IDH mutant gliomas (Koivunen et al.,
2012). These data seem incompatible with the finding that HIF1α
protein levels are increased in IDH mutant tumors. However,
these data may suggest that d-2HG quantitatively shifts the dose-
response linking HIF activation to hypoxia, leading to a blunted
HIF response for a given level of hypoxia. In support of this
idea, HIF elevation in IDH mutant tumors is usually confined
to areas of necrosis and presumed severe hypoxia (Williams et al.,
2011).
Collectively, the data support the concept that IHD muta-
tions promote oncogenesis through d-2HG-induced inhibition
of α-KG-dependent enzymes, such as TET2 and histone demethy-
lase. This idea further suggests a paradigm whereby oncogenic
alterations in core cellular metabolic pathways could lead to neo-
plastic progression by dysregulating the epigenetic machinery in
hematopoietic and glial progenitors. Mutations of IDH1 and IDH2
in combination with microenvironmental effects in certain tumor
types are likely the driver mutations that are responsible for the
malignant phenotype, rather than simply epiphenomena (Dang
et al., 2009; Figueroa et al., 2010; Xu et al., 2011; Koivunen et al.,
2012; Losman et al., 2013).
IDH MUTATIONS IN AML
Mardis and colleagues (Mardis et al., 2009) used next generation
(massive parallel) DNA sequencing analysis of the genome of an
AML patient with a normal karyotype and discovered an IDH1
mutation. Subsequently, this finding was validated in 187 AML
patients in whom 8% had IDH1 mutations. To date, there have
been ∼20 published studies on IDH1 and IDH2 mutations that
have included ∼8,000 adult and ∼800 pediatric patients (Mardis
et al., 2009; Abbas et al., 2010; Boissel et al., 2010; Chou et al.,
2010, 2011b; Figueroa et al., 2010; Gross et al., 2010; Marcucci
et al., 2010; Paschka et al., 2010; Schnittger et al., 2010; Thol et al.,
2010a; Wagner et al., 2010; Ward et al., 2010; Andersson et al.,
2011; Damm et al., 2011; Green et al., 2011; Pigazzi et al., 2011;
Rakheja et al., 2011a; Patel et al., 2012). These studies have focused
on the frequency and prognostic influence of IDH mutations in
the context of other genetic mutations and prognostic markers.
Isocitrate dehydrogenase 1/2 mutations are almost mutually
exclusive in AML, as only rare cases (<0.5%) harbor both IDH1
and IDH2 mutations (Abbas et al., 2010; Paschka et al., 2010; Green
et al., 2011). This low frequency of concurrent mutations sug-
gests that the biological effects of IDH1 and IDH2 are similar, and
this idea is corroborated by the similar impact of these mutations
on the distribution of cytosine methylation and the global DNA
methylation profile in AML cells (Figueroa et al., 2010).
For IDH1R132 mutations in AML, as in other tumors, five major
different amino acid substitutions for arginine (R) have been
detected: cysteine (R132C), leucine (R132L), glycine (R132G), his-
tidine (R132H), and serine (R132S) (Mardis et al., 2009; Abbas
et al., 2010; Chou et al., 2010; Ho et al., 2010; Marcucci et al.,
2010; Schnittger et al., 2010; Wagner et al., 2010; Patel et al.,
2011a). R132C (∼30%) and R132H (∼50%) are the most com-
mon mutations in AML. The mutational profile is slightly different
in gliomas, in which R132H (∼90%) is most common and R132C
is uncommon (∼4%) (Yan et al., 2009; Chou et al., 2010). For
IDH2R140 mutations, three different amino acid substitutions have
been detected: glutamine (R140Q), leucine (R140L), and trypto-
phan (R140W). Of these mutations, R140Q is the most common
by far, seen in ∼95% of AMLs with mutated IDH2 at R140. For
IDH2R172 mutations, almost all involve replacement of arginine
by lysine (R172K), except rare cases in which arginine is replaced
by methionine (R172M) (Chou et al., 2011b).
In unselected adults with AML, in a total of 6,877 patients,
IDH1 and IDH2 mutations have been identified in 7.3 and 9.7%
of cases, respectively. The frequencies of IDH1 and IDH2 muta-
tions are higher in cytogenetically normal (CN) versus abnormal
AML patients (11 versus 3.5% for IDH1 mutations; and 16 ver-
sus 3.8% for IDH2 mutations), placing them among the most
common molecular aberrations in CN-AML. Within the group of
IDH2 mutations, IDH2R140 mutations are most common (∼80%)
whereas IDH2R172 mutations occur in ∼2% of unselected AML
and about 2.5% of CN-AML patients.
Acute myeloid leukemia patients with IDH1R132 or IDH2R140
mutations are more frequently older at diagnosis as compared
with wild type AML patients. AML patients with IDH2R172 muta-
tion are usually older with lower white blood cell (WBC) counts.
The frequency of IDH1/2 mutations is substantially lower in
pediatric (∼1–2%) than in adult patients with AML. IDH2R172
mutations have not been observed in children (Marcucci et al.,
2010). In most studies to date, there has been little focus correlat-
ing IDH1/2 mutations with morphologic findings in AML. Most
cases with IDH1/2 mutations have been classified as AML, not
otherwise specified, with or without maturation. A rare morpho-
logic subset of AML characterized by cuplike nuclei appears to
commonly carry IDH1/2 mutations. In one study, 8 of 12 (67%)
patients with AML with cuplike nuclei patients harbored either
IDH1R132 or IDH2R140 mutations (Rakheja et al., 2011a). AML
with cuplike nuclei also have a high frequency of NPM1 muta-
tions and FLT3 internal tandem duplication (FLT3-ITD) (Chen
et al., 2009).
Patients with AML carrying IDH1/2 mutations have a higher
frequency of NPM1 mutations compared with AML wild type for
IDH1/2. In general, IDH1/2 mutations are less frequent in AML
patients with activating FLT3 mutations, CEBPA mutations, and
are largely absent in patients with AML associated with recur-
rent chromosomal abnormalities, such as t (15;17), t (8;21), inv(16)
(Chou et al., 2010, 2011b; Patel et al., 2011a). IDH2R172 mutation
also appears to be virtually mutually exclusive with other genetic
abnormalities (Marcucci et al., 2010; Paschka et al., 2010; Green
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et al., 2011; Patel et al., 2011a), thereby identifying a novel subset
of patients among the∼3% of CN-AML adult patients for whom
no prognostic gene mutation has been reported to date.
The prognostic effect of IDH mutations in adult AML patients
has been intensively studied, but remains a matter of discussion.
In general, there have been no differences in response to therapy
and survival between IDH1/2-mutated versus IDH1/2-wild type
AML patients (Abbas et al., 2010; Chou et al., 2010; Thol et al.,
2010a; Wagner et al., 2010; Marcucci et al., 2011). The impact of
an IDH1or IDH2 mutation,however,does seem to have prognostic
importance if results are stratified according to cytogenetic data,
FLT3-ITD and NPM1 mutation status, and type of IDH mutation
(Boissel et al., 2010; Green et al., 2010, 2011; Marcucci et al., 2010;
Paschka et al., 2010; Schnittger et al., 2010). IDH1 mutations may
predict higher risk of relapse and shorter survival in the subset of
CN-AML patients with mutated NPM1 and absence of FLT3-ITD
(molecular low-risk group) (Marcucci et al., 2010; Paschka et al.,
2010). In addition, there is some evidence that IDH2R172 muta-
tions confer a poorer prognosis whereas IDH2R140 mutations have
no impact on survival or may confer a favorable outcome (Boissel
et al., 2010; Marcucci et al., 2010; Chou et al., 2011b; Green et al.,
2011; Patel et al., 2012). Future prospective studies and clinical tri-
als are needed to assess the prognostic impact of each type of IDH
mutation in AML patients within the context of other molecular
aberrations.
In pediatric AML patients, there is an association between
NPM1 and IDH mutations, as has been described in adult AML
patients. However, in contrast with adults, IDH mutations are not
associated with a normal karyotype in childhood AML. Instead,
IDH mutations have been observed in pediatric AML patients with
good-risk cytogenetics, t (8;21), and t (15;17). In addition, neither
type of IDH mutation occurs in children <3 years, affirming the
distinctiveness of infant AML.
IDH MUTATIONS IN MYELODYSPLASTIC SYNDROMES AND
MYELOPROLIFERATIVE NEOPLASMS
Isocitrate dehydrogenase mutations occur at low frequency in
patients with myelodysplastic syndromes (3.6–5%) and patients
with Philadelphia chromosome/BCR-ABL1 negative myeloprolif-
erative neoplasms in chronic phase (2–4%). Mutated cases have
an increased frequency of progression to AML, ranging from 7.5
to 31% in different studies (Abbas et al., 2010; Green and Beer,
2010; Pardanani et al., 2010; Tefferi et al., 2010, 2011; Thol et al.,
2010b). In patients with myeloproliferative neoplasms character-
ized by JAK2 and IDH1/2 mutations, it is tempting to speculate
that these gene mutations have an additive or cooperative effect to
facilitate leukemogenesis. The JAK2 mutation may offer a prolifer-
ative advantage whereas IDH1/2 mutations may disrupt epigenetic
remodeling. Mutations in IDH1 or IDH2 mutations are absent
or very rare in patients with chronic myelogenous leukemia in
chronic phase (Abbas et al., 2010).
IDH MUTATIONS IN GLIOMAS
The first report of an IDH mutation in gliomas occurred in 2008
after over 20,000 protein coding genes were analyzed in 22 human
GBM samples (Parsons et al., 2008). In this study, IDH1R132 point
mutations were detected in 12% of GBM samples. The authors
observed that IDH1mutations occurred in younger adults, in most
of the secondary GBM samples, and that mutation was associ-
ated with increased overall survival. The fact that IDH1 mutations
occurred in secondary GBM prompted the same group to deter-
mine the frequency of IDH1 mutations in the low-grade gliomas.
Targeted sequencing of IDH1 and IDH2 in 445 central nervous sys-
tem tumors revealed IDH1/2 mutations in 90% of cases of diffuse
astrocytoma (grade II), 84% of oligodendroglioma (grade II), 73%
of anaplastic astrocytoma (grade III), 94% of anaplastic oligoden-
droglioma (WHO grade III), and 85% of secondary GBM (grade
IV) (Yan et al., 2009). Several follow-up studies encompassing
thousands of central nervous system neoplasms have found sim-
ilar frequencies of IDH1 and IDH2 mutations (Hartmann et al.,
2009; Nobusawa et al., 2009; van den Bent et al., 2010; Jha et al.,
2011; Thon et al., 2012). Similar to what has been observed in
AML patients, IDH1 and IDH2 gene mutations in gliomas are
mutually exclusive, heterozygous, and restricted to the R132 site
of IDH1 and the R172 site of IDH2. The discovery of IDH muta-
tions in gliomas has allowed for further characterization of the
sequence of events in glioma pathogenesis. The detection of IDH
mutations in most low-grade gliomas and secondary GBM sug-
gests that IDH1 mutation is an early event in pathogenesis. Cases
of primary GBM that do not show IDH mutations are genetically
distinct.
POTENTIAL UTILITY OF DETECTING IDH MUTATIONS IN GLIOMAS
Detection of an IDH mutation, either directly in surgical speci-
mens or indirectly by measuring d-2HG levels in the brain, has
practical implications. The presence of IDH mutation in a GBM
in a patient without a prior history of a brain lesion would sup-
port a diagnosis of secondary GBM, which portends a better, albeit
still dismal prognosis. Like primary GBM, grade I central nervous
system tumors, such as pilocytic astrocytoma, and non-neoplastic
brain tissue lack IDH mutations. Distinguishing rare infiltrating
neoplastic cells from reactive gliosis in surgical biopsy specimens
can be difficult, and the presence of IDH mutation would support
a neoplastic process. An additional implication includes distin-
guishing diffuse astrocytoma (grade II) from pilocytic astrocytoma
(grade I). Although associated with a better prognosis, the pres-
ence of IDH mutations in gliomas does not predict a response to
therapy (Capper et al., 2010; Preusser et al., 2011).
POTENTIAL UTILITY OF IDH MUTATIONS AS A FOLLOW-UP MARKER
Isocitrate dehydrogenase 1 and 2 mutations appear to be stable. In
one study of 225 AML patients with wild type IDH at diagno-
sis, not a single patient acquired an IDH mutation during clinical
follow-up (Chou et al., 2010). In addition, in patients with IDH
mutated AML at diagnosis, the same mutation persisted in over
95% of IDH1-mutated and IDH2-mutated AML cases at relapse
(Chou et al., 2010, 2011b; Schnittger et al., 2010; Thol et al.,
2010a). From a biological perspective, this stability suggests that
IDH mutations may be a primary event that is involved early in
leukemogenesis and/or maintenance of the leukemic phenotype.
Recent data (Dinardo et al., 2013) suggest that elevated levels of d-
2HG in serum, higher than 700 ng/ml could segregate patients
with and without IDH mutations. Furthermore, IDH mutant
patients with d-2HG levels >200 ng/ml at complete remission
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experienced shorter overall survival compared to those with d-
2HG<200 ng/ml. These data confirm that serum measurement of
an oncometabolite can provide useful information for diagnosis,
treatment response, and prognosis.
METHODS OF DETECTING IDH MUTATIONS AND THE
ONCOMETABOLITE D-2HG
Isocitrate dehydrogenase mutations can be detected by a num-
ber of methods including polymerase chain reaction (PCR)-based
assays (Felsberg et al., 2010; Meyer et al., 2010; Patel et al., 2011b;
Rakheja et al., 2011a), expression of IDH1 mutant protein in tumor
tissue as detected by mutation specific antibody using immuno-
histochemistry (Andrulis et al., 2010; Capper et al., 2010), and
indirectly by detecting the putative oncometabolite, d-2HG, by
mass-spectrometry in vitro or by magnetic resonance spectroscopy
in vivo (Gross et al., 2010; Rakheja et al., 2011b; Choi et al., 2012;
Sahm et al., 2012).
Polymerase chain reaction-based assays include amplification
of genomic DNA at exon 4 of IDH1 (IDH1R132) and IDH2
(IDH2R140 or IDH2R172) followed by Sanger sequencing, restric-
tion endonuclease digestion and high-resolution melting curve
analysis, and pyrosequencing. Unfortunately, these methods have
a relatively low sensitivity, for example, ∼20% for heterozygous
mutations by Sanger sequencing. More sensitive methods, such as
allele-specific PCR, also can be performed to detect of IDH1/IDH2
mutations. More recently, next generation sequencing methods
have been applied to the detection of IDH1/2 mutations. With
coverage of 500 times, the sensitivity of this approach is ∼5%.
These more sensitive assays can be used to detect mutations in
treated AML patients in whom bone marrow samples have low
blast counts as well as for the detection of early relapse or minimal
residual disease.
Currently, only IDH1 mutant protein, IDH1R132 can be
detected by immunohistochemistry using the H09 clone (Dianova,
Hamburg, Germany) (Andrulis et al., 2010; Capper et al., 2010;
Sahm et al., 2012). This antibody has been examined in gliomas,
but has not yet been evaluated comprehensively in the myeloid
neoplasms. Future development of a monoclonal antibody tar-
geted at the IDH2 mutant proteins, IDH2R140 or IDH2R172, would
be helpful and convenient for detecting these mutations.
In the laboratory at Children’s Medical Center of Dallas, exon
4 and flanking intronic regions of IDH1 and IDH2 are sequenced
(Rakheja et al., 2011a,b,c). PCR amplification is followed by Sanger
sequencing. At MD Anderson Cancer Center, a Sanger based assay
has been recently transitioned to a next generation sequencing
assay used to detect IDH1/2 mutations in AML patients at time of
initial diagnosis. The metabolites,d-2HG and l-2-hydroxyglutaric
acid (l-2HG), are measured using liquid chromatography-tandem
mass spectrometry (LC-MS/MS) as described previously (Rakheja
et al., 2011a,b,c).
Detection of d-2HG in tumor tissue by mass-spectrometry
in vitro or by magnetic resonance spectroscopy in vivo offers
an advantage in that potentially all mutations are detectable, as
all mutations generate this oncometabolite (Gross et al., 2010;
Rakheja et al., 2011b,c; Choi et al., 2012; Sahm et al., 2012). This
non-invasive detection of d-2HG may prove to be valuable in
diagnosis and providing prognostic biomarker. It should be noted
that archival formalin-fixed paraffin-embedded tumor specimens
may not be optimal for detecting d-2HG because this metabolite
can be lost during the routine embedding process (Sahm et al.,
2012).
IMPLICATIONS FOR FUTURE TREATMENT
Isocitrate dehydrogenase 1/2 mutations are thought to be one of
the driver mutations in AML and early events in the pathogenesis
of gliomas. The common feature of IDH1 and IDH2 mutations
is the ability of the respective enzymes to exhibit neomorphic
activity, not characteristic of the wild type enzymes, that facil-
itate production of d-2HG. Therefore, targeted therapies that
inhibit the neomorphic function of mutant IDH enzymes or
DNA hypomethylating agents might reverse the associated epige-
netic patterning and may promote myeloid or glial differentiation
and improve outcome in patients with IDH1/2-mutated tumors.
Recently, IDH inhibitors have been shown to produce cytostatic
effects and cellular differentiation in leukemia and glioma cells
(Rohle et al., 2013; Wang et al., 2013). It is currently unknown,
however, whether these inhibitors can induce a permanent state
of differentiation. The survival of viable tumor cells still contain-
ing a potentially transforming constellation of mutations makes it
important to determine whether the therapeutic effects will persist
over long time frames.
CONCLUSIONS AND FUTURE PERSPECTIVES
IDH1R132, IDH2R140, and IDH2R172 mutations represent a novel
class of point mutations in patients with AML and glioma. In AML
patients, it is possible that IDH1R132, IDH2R140, and IDH2R172
mutations represent molecular or clinically distinctive subgroups,
with IDH1R132 and IDH2R140 more frequently accompanied by
normal cytogenetics and NPM1 mutation, whereas IDH2R172 is
frequently the only mutation detected and portends a poor prog-
nosis. In glioma patients, IDH mutations are present in grade II
and III gliomas as well as secondary GBM. Whether these dif-
ferent mutation types represent distinctive subgroups of glioma
patients is less understood. As both IDH1 and IDH2 mutations
result in the generation of the putative oncometabolite, d-2HG,
this oncometabolite can be measured directly in tumor sam-
ples and serum. Screening for the presence of d-2HG could be
used as an assay to detect IDH mutations, monitor therapeutic
response, and potentially uncover novel IDH mutations. Impor-
tantly, expression of mutant IDH1/2 induces a global increase in
DNA hypermethylation and inhibits TET2-induced cytosine 5-
hydroxymethylation, suggesting thatTET2 and IDH1/2 mutations
constitute a distinct mutational class in these tumors in which the
epigenetic state is altered. Furthermore, this biologic effect is an
important consideration for developing a therapeutic agent that
can target dysregulated IDH enzymes in addition to induction
of DNA hypomethylation. Inhibitors to mutant IDH have been
shown recently to produce cytostatic effects and cellular differen-
tiation in leukemia and glioma cells and seem promising. Future
studies are important to determine whether these inhibitors can
induce a permanent state of differentiation, and their therapeutic
effects and toxicity in clinical trials. Discovering IDH mutations
is an example of a pathologic finding that links disruption of
metabolism to oncogenesis.
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